Pushing the boundary of cancer diagnostics through microfluidic technologies
-
-
REFERENCES
[1] Murphy, J.B., and Sturm, E. (1925). Primary lung tumors in mice following the cutaneous application of coal tar. J. Exp. Med. 42: 693−700. DOI: 10.1084/jem.42.5.693. [2] Nielsen, T.O., Parker, J.S., Leung, S., et al. (2010). A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer. Clin. Cancer Res. 16: 5222. DOI: 10.1158/1078-0432.CCR-10-1282. [3] Office of Science and Engineering Laboratories. (2021). Microfluidics program: Research on microfluidics-based medical devices. US Food and Drug Administration: https://www.fda.gov/medical-devices/medical-device-regulatory-science-research-programs-conducted-osel/microfluidics-program-research-microfluidics-based-medical-devices#:~:text=The%20Microfluidics%20Program%20focuses%20on. [4] Jonasson, O. (1958). The viability of circulating cancer cells in experimental cancer. Surg. Forum. 9: 577−580. [5] Kalluri, R., and McAndrews, K.M. (2023). The role of extracellular vesicles in cancer. Cell 186: 1610−1626. DOI: 10.1016/j.cell.2023.03.010. -
ABOUT THIS ARTICLE
Cite this article:
Wong AH. (2023). Pushing the boundary of cancer diagnostics through microfluidic technologies. The Innovation Medicine 1(1), 100005. https://doi.org/10.59717/j.xinn-med.2023.100005
Welcome!
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Export File
Citation
Wong AH. (2023). Pushing the boundary of cancer diagnostics through microfluidic technologies. The Innovation Medicine 1(1), 100005. https://doi.org/10.59717/j.xinn-med.2023.100005
Format
Content
DownLoad:
-
Figure 1.
Examples of microfluidic technologies applied to (A) circulating tumor cell (CTC) isolation and (B) cell-based drug screening
